Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Vasotec in NHLBI studies

Executive Summary

Two randomized, controlled trials are being sponsored by the National Heart, Lung & Blood Institute to determine the effectiveness of enalapril in improving survival of patients with left ventricular dysfunction. Effects of the ACE inhibitor on quality of life, biventricular functions, arrhythmias, exercise tolerance, neurohormonal changes and major morbidity will also be assessed. Studies, which are being conducted at 23 centers in the U.S., Canada and Belgium, will enroll 4,500 asymptomatic congestive heart failure patients to the prevention trial and 2,600 symptomatic patients to the treatment trial.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel